NDV-01 (Sustained-release Gemcitabine-docetaxel)

Gemcitabine-docetaxel sustained-release formulation · Relmada Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NDV-01 (Sustained-release Gemcitabine-docetaxel), covering 2026-03-11 to 2026-03-11. Get the full timeline:

Most recent: Clinical Trial Update: A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer [Phase 3]

See pricing